La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Lipum Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Ola Sandborgh

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.2%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	3.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Ola Sandborgh (58 yo)

less than a year

Mandato

Mr. Ola Sandborgh serves as CEO at Lipum AB (publ) since December 01, 2023. He has experience from the pharmaceutical industry where he has worked in leading roles in different commercial, innovation and b...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Olle Hernell	Co-Founder & Director	no data	SEK 303.50k	1.61% SEK 4.2m
Gustav Kihlstrom	Independent Chairman of the Board	3.3yrs	Nessun dato	Nessun dato
Björn Löwenadler	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Carl-Johan Spak	Independent Director	1.3yrs	Nessun dato	0.017% SEK 43.4k
Anders Fasth	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Lennart Lundberg	Member of Scientific Advisory Board	3.2yrs	Nessun dato	Nessun dato
Asa Hansdotter	Independent Director	3.3yrs	Nessun dato	Nessun dato
Kristian Sandberg	Independent Director	4.5yrs	Nessun dato	Nessun dato
Rikard Holmdahl	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Solbritt Dahlqvist	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Asa Magnusson	Director	less than a year	Nessun dato	Nessun dato

3.2yrs

Durata media

69.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di LIPUM sono considerati esperti (durata media dell'incarico 3.1 anni).

Lipum Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Lipum AB (Publ) Welcomes Peter Hovstadius as Chief Medical Officer

High number of new directors

Lipum AB (publ) Announces Nomination Committee Appointments

Lipum AB (Publ) Appoints Ola Sandborgh as Chief Executive Officer, Effective from December 1, 2023

Lipum AB (Publ) Appoints Karin Franck-Larsson as CMO

Lipum Elects Carl-Johan Spak as New Board Member

Recent updates

Lipum AB (Publ) Welcomes Peter Hovstadius as Chief Medical Officer

New major risk - Financial position

High number of new directors

Lipum AB (publ) Completes Multiple Dose Part of the Phase I Clinical Study

Lipum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 79.714945 million.

Lipum Recommends Shareholders to Not Accept Mandatory Cash Offer

Lipum Recommends Shareholders to Not Accept Mandatory Cash Offer

Forecast to breakeven in 2025

Lipum AB (publ) has filed a Follow-on Equity Offering.

Lipum AB (publ) has filed a Follow-on Equity Offering.

Lipum AB (publ) Reports Positive Interim Results from Clinical Phase 1 Study Showing that SOL-116 Reduces Plasma BSSL Levels in Healthy Subjects

Lipum AB (Publ) Receives Funding from Vinnova for an Eurostars Application

Lipum AB (publ) Announces Nomination Committee Appointments

Lipum AB (Publ) Appoints Ola Sandborgh as Chief Executive Officer, Effective from December 1, 2023

New major risk - Revenue and earnings growth

Lipum AB (Publ) Appoints Karin Franck-Larsson as CMO

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Lipum Elects Carl-Johan Spak as New Board Member

Chief Executive Officer recently bought kr161k worth of stock

Lipum AB (publ) Announces the Nomination Committee for the 2023 Annual General Meeting

Chief Executive Officer recently bought kr157k worth of stock

Lipum AB (Publ) Has Initiated A Phase 1 Clinical Study with Its Drug Candidate Sol-116

Lipum AB (publ) announced that it has received SEK 38.999963 million in funding from Flerie Invest AB

Lipum AB (publ) Gets Approval to Start Phase 1 Clinical Trial with Drug Candidate Sol-116

Lipum AB (publ) Appoints Helena Bergström as Chief Medical Officer

Lipum Reports Completion of GLP Toxicology- and Safety Program on the Candidate Drug (SOL-116)

Chief Executive Officer recently bought kr195k worth of stock

Lipum AB (Publ) Reports Gmp Production of Sol-116 Successful

Lipum Recruits Fredrik Seijsing as Scientist

Lipum AB (publ) Initiates GMP-Production for Clinical Trials

Lipum Is At the Final Step Before Clinical Phase

AMMINISTRATORE DELEGATO

Mandato

Membri del Consiglio di amministrazione

Durata media

Età media